TY - JOUR
T1 - Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms
T2 - Treatment Considerations and Unmet Needs
AU - Liu, Angela
AU - Naymagon, Leonard
AU - Tremblay, Douglas
N1 - Funding Information:
D.T. receives clinical research funding from Astellas Pharma and consulting fees from AbbVie and CTI Biopharma. The rest of the authors have no financial conflicts of interest to disclose. The funders had no role in the design of the study; in the collection, analysis, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Publisher Copyright:
© 2022 by the authors.
PY - 2023/1
Y1 - 2023/1
N2 - Patients who develop splanchnic vein thrombosis (SVT) in the setting of a myeloproliferative neoplasm (MPN) are at risk for complications including portal hypertension, bleeding, thrombosis, and death. Prompt multidisciplinary treatment is thus necessary to prevent long-term sequelae. However, optimal management strategies are not well established due to a paucity of data. In this review, we very briefly discuss the epidemiology, pathophysiology, and prognosis of MPN-SVT and then more comprehensively explore treatment considerations of MPN-SVT, including anticoagulation, endovascular/surgical intervention, and cytoreductive therapy. We will also highlight current gaps in our knowledge of MPN-SVT and conclude by suggesting future directions to optimize the treatment of MPN-SVT and improve outcomes.
AB - Patients who develop splanchnic vein thrombosis (SVT) in the setting of a myeloproliferative neoplasm (MPN) are at risk for complications including portal hypertension, bleeding, thrombosis, and death. Prompt multidisciplinary treatment is thus necessary to prevent long-term sequelae. However, optimal management strategies are not well established due to a paucity of data. In this review, we very briefly discuss the epidemiology, pathophysiology, and prognosis of MPN-SVT and then more comprehensively explore treatment considerations of MPN-SVT, including anticoagulation, endovascular/surgical intervention, and cytoreductive therapy. We will also highlight current gaps in our knowledge of MPN-SVT and conclude by suggesting future directions to optimize the treatment of MPN-SVT and improve outcomes.
KW - essential thrombocythemia
KW - myelofibrosis
KW - myeloproliferative
KW - polycythemia vera
KW - splanchnic vein
KW - thrombosis
UR - http://www.scopus.com/inward/record.url?scp=85145559123&partnerID=8YFLogxK
U2 - 10.3390/cancers15010011
DO - 10.3390/cancers15010011
M3 - Review article
AN - SCOPUS:85145559123
SN - 2072-6694
VL - 15
JO - Cancers
JF - Cancers
IS - 1
M1 - 11
ER -